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ABSTRACT

ANGIOTENSIN II –MEDIATED REGULATION OF THE HUMAN
ANGIOTENSIN II TYPE 1 RECEPTOR GENE

Xylophone V. A.Victor
Department of Chemistry and Biochemistry
Doctor of Philosophy

The physiological responses of angiotensin II (Ang II) are mediated across the
cell membrane through the angiotensin II type 1 receptor (AT1R), a heptahelical
membrane protein coupled to trimeric G-proteins on the cytosolic side. AT1R on binding
its ligand, Ang II, leads to downregulation of cell-surface receptor and also its mRNA.

We have investigated whether the 3′- and 5′-untranslated regions of the human
AT1R mRNA mediate the degradation of hAT1R mRNA by post-transcriptional
mechanisms in human adrenocortical carcinoma cell line (H295R cells). Protein kinase
C

(PKC)

activator,

phorbol-12-myristate-13-acetate

(PMA),

showed

downregulation of hAT1R mRNA is mediated by the PKC pathway.

that

the

Experiments

performed in the presence of cycloheximide and/or Ang II demonstrated that protein
translation is essential for hAT1R mRNA downregulation.

In vitro cell-free RNA degradation assays did not show any increase in the rate of
degradation of in vitro transcribed RNA in the presence of cytoplasmic extract from cells
treated with Ang II, which suggested that hAT1R steady state mRNA levels may not be
mediated by changes in mRNA degradation rates.

Luciferase assay after transient

transfection of chimeric plasmids of luciferase and hAT1R-3′-UTR showed that Ang II
stabilizes the mRNA rather than increase the rate of degradation. Similar results were
observed in Northern blot experiments utilizing β-globin fusion with 3′-UTR that led to
stabilization of the chimeric mRNA. Luciferase fusion constructs with both 5′- and 3′UTRs demonstrated that UTRs are not involved in the Ang II-mediated degradation of
hAT1R mRNA. Experiments using transcriptional inhibitor actinomycin D demonstrated
that the hAT1R mRNA is not destabilized in response to Ang II activation in H295R
cells.

Nuclear run-on assay performed in the adrenocortical carcinoma cells
demonstrated that the Ang II-stimulated downregulation of hAT1R is mediated by
transcriptional inhibition. The transcription of hAT1R mRNA was reduced by 44 and
70% after Ang II treatment for 1 and 2 hours, respectively. Taken together, these
findings suggest that the Ang II-induced downregulation of hAT1R steady state mRNA
levels is transcriptionally controlled and is not mediated by post-transcriptional
mechanisms.
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CHAPTER 1

INTRODUCTION

Renin-Angiotensin System
The classical renin-angiotensin system (RAS) consists of renin, angiotensinconverting enzyme and angiotensinogen (Fig. 1.1). Renin is synthesized in the kidney,
stored in the afferent arterioles and released in response to hemodynamic, neurogenic,
and ionic signals (1, 2). Renin, an aspartyl protease, has a very high specificity for its
substrate angiotensinogen (3).

Angiotensinogen is a 58 kilodaltons (Kd) protein

synthesized and released from the liver (4). Renin cleaves angiotensinogen to release the
amino terminal decapeptide angiotensin I (Ang I).

Angiotensin-converting enzyme

(ACE), which is expressed endothelially, then cleaves Ang I to release the two carboxy
terminal amino acids. The resulting octapeptide is designated angiotensin II (Ang II) (5).
Ang II is a potent vasoconstrictor while Ang I is biologically inactive.

Alternate

pathways for the production of Ang II by other enzymes also exist (Fig. 1.1). Ang I is
cleaved by cathepsin G (6), chymostatin-sensitive Ang-II-generating enzyme (CAGE) or
chymase (7, 8) to form Ang II. Ang II is also known to be generated by the action of
cathepsin D, tonin (9) and tissue plasminogen activator (t-PA) on angiotensinogen. Ang
II is further acted upon by aminopeptidase A and aminopeptidase N sequentially to
produce angiotensin III (Ang III) and angiotensin IV (Ang IV) respectively.

Circulating versus Tissue RAS
The RAS components form the circulating endocrine system that regulates salt
balance and blood pressure. However, all RAS components are also expressed in various

3

Figure 1.1 Schematic representation of the renin-angiotensin system.
The classic cascade of the RAS is shown in block arrows. Alternative means shown in dotted arrows. Ang
2-8, angiotensin III; Ang 3-8, angiotensin IV; CAGE, chymostatin-sensitive Ang-II-generating enzyme; tPA, tissue plasminogen activator; AT1 Receptor, Angiotensin II type 1 receptor; AT2 Receptor,
Angiotensin type 2 receptor. Lavoie and Sigmund, 2003 (10).
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tissues including the brain (11, 12), heart (11), vasculature (11), adipose tissue (13),
gonads (14), pancreas (15), placenta (16), and kidney (11); and thus Ang II can be
synthesized locally. The tissue RAS plays an important role in normal physiological
processes and has been implicated in pathophysiological conditions such as hypertension,
congestive heart failure and cardiovascular hypertrophy (17-19). The importance of
tissue RAS is supported by clinical observations; 1) the antihypertensive actions of ACE
inhibitors are better correlated with inhibition of tissue ACE rather than plasma ACE, and
2) hypertensive patients with normal or even low levels of systemic RAS activity can be
effectively treated with inhibitors of RAS (20).

Physiological Functions of Ang II
The primary function of Ang II is the modulation of Na+ reabsorption and H2O
retention in kidney in response to changes in extracellular fluid volume (21, 22). Thus,
Ang II plays a major role in the regulation of blood pressure. Ang II also produces
vasoconstriction. The responsiveness of blood vessels to Ang II varies between tissues;
while blood vessels in the kidney, mesentery and skin are highly responsive, blood
vessels in the brain, lung and skeletal muscle are less responsive (23). Ang II also acts on
the adrenal gland to increase the synthesis and release of aldosterone, which promotes
reabsorption of Na+ in the renal distal tubule (24).
Ang II has also been demonstrated to be a potent growth factor for vascular
smooth muscle cells (VSMC) (25, 26), renal mesangial cells (27), cardiomyocytes (28)
and cardiac fibroblasts (29). This cell proliferative activity is believed to play a primary
role in cardiac remodeling (30). In the liver, Ang II increases the breakdown of glycogen
5

and gluconeogenesis (108). Ang II stimulates cardiac fibroblast matrix formation and
modulates cardiac remodeling (31). Ang II is also involved in pathological hypertrophy,
and increased inotropy and chronotrophy in the heart (31). Ang II also acts on the brain
to release vasopressin, luteinizing hormones, oxytocin and corticotrophin in addition to
stimulating drinking behavior to maintain hemostasis.

Angiotensin Receptors
Ang II mediates its effects in various tissues by binding to cell surface receptors
(32). These receptors are heptahelical membrane proteins (Fig. 1.2) that bind trimeric Gproteins on the cytoplasmic side.

Ang II has been demonstrated to bind two

pharmacologically distinct receptors, angiotensin II type 1 receptor (AT1R) (33, 34) and
angiotensin II type 2 receptor (AT2R) (35, 36). These two receptors are expressed in a
tissue-specific manner. In humans, the AT1R is expressed in adrenals, heart, kidney and
placenta (35). In contrast to the AT1R, AT2R is expressed in human fetal kidney, adult
lung and heart (36, 37). AT1R mediates a wide variety of physiological responses of Ang
II including vasoconstriction, cell proliferation, angiogenesis, matrix synthesis, and
aldosterone synthesis and release. AT1R also mediates the inflammatory responses of
Ang II by increasing the vascular permeability (38, 39) and recruitment of inflammatory
cells by activation of immune cells (40). However, the physiological responses of AT2R
are not well known. AT2R has been implicated in development (41), cell differentiation,
tissue repair (42, 43) and apoptosis (44). Arterial hypertrophy, remodeling and fibrotic
changes caused by Ang II which were attributed to AT1R mediation have been
challenged by studies using AT1R and AT2R blockers (73). Other studies have failed to
6

resolve these contradictions (74). However, recent research has demonstrated that AT2R
antagonizes the effects of AT1R (75). Further studies need to be undertaken to elucidate
the role of AT2R.

Signal Transduction
Ang II is known to activate various cellular signaling pathways in cells.
Classically, Ang II activates the trimeric G-proteins upon binding its cell surface
receptor, AT1R (Fig. 1.2). The trimeric G-proteins in turn activate phospholipases C
(45), D (46) and A2 (47) (Fig. 1.3). Each of these enzymes lead to production of second
messengers that mediate various responses. Activation of AT1R leads to rapid production
of 1,4,5-inositol triphosphate (IP3) and a sustained release of diacylglycerol. Both of
these second messengers lead to activation of protein kinase C (PKC) (48).
AT1R activation is also associated with increased tyrosine phosphorylation and
activation of mitogen activated protein kinases (MAPK) (Fig. 1.4). Ang II binding to
AT1R leads to activation of non-receptor, and receptor tyrosine kinases. The various
non-receptor tyrosine kinases that are activated by Ang II include Src family kinases,
Janus kinases (JAK), tyrosine kinases (TYK), focal adhesion kinases (FAK), Ca2+dependent tyrosine kinases and p130Cas (Fig. 1.4). Src plays an important role in Ang
II-induced phosphorylation of PLC-γ and IP3 formation (49). Src, intracellular Ca2+ and
PKC regulate Ang II-induced activation of p130Cas, which is involved in integrinmediated cell adhesion. AT1R stimulates JAK2 and TYK2, members of the JAK family.
Activation of JAK leads to phosphorylation of the signal transducer and activator of
transcription (STAT) proteins p91/84 (STAT1α/β), p113 (STAT2) and p92 (STAT3)
7

Figure 1.2 Schematic representation of human AT1 receptor.
The membrane spanning regions are indicated in boxes. The disulfide linkages are shown as bold lines.
The N-glycosylation on the residues is indicated as a Y. Timmermans et al., 1993 (34).
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which are transcription factors. Ang II-induced tyrosine phosphorylation and nuclear
translocation of STAT1 require JAK2 and p59 Fyn kinase. The JAK-STAT signaling
pathway activates early growth response genes and may be involved in Ang II-mediated
vascular growth, remodeling and repair (50). Ang II promotes cell migration and induces
changes in cell shape and volume by activating FAK-dependent signaling pathways (51).
FAK activation leads to its binding the Grb2-Sos-Ras complex. This in turn leads to
activation of ERK1/2 which are involved in the activation of transcription factors. Ang
II-stimulated hyperplasia in cultured rat cells is mediated by PI3K (52). PI3K inhibitors,
wortmannin and LY29002, block the Ang II-mediated PI3K activation. However, the
mechanisms by which Ang II mediates the activation of PI3K are not well understood.
The receptor tyrosine kinases (RTK) that are modulated by Ang II include
epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor
(PDGFR) and insulin-like growth factor receptor (IGFR) (53).

The mechanism of

transactivation of the RTKs by Ang II has not been elucidated.

However, the

transactivation plays an important role in Ang II signaling. For example, in rat VSMC,
both Ang II-induced nuclear proto-oncogene expression and increase in c-fos protein
were prevented by treatment with EGFR kinase inhibitor (54).

9

Figure 1.3 Schematic representation of the Ang II activation of intracellular second messengers.
AT1R activates phospholipases A2, C and D which then generate the phospholipid second messengers.
Ushio-Fukai et al., 1998 (48).
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Figure 1.4 Schematic representation of the tyrosine kinase pathways activated by Ang II through
AT1R.
Ang II-mediated activation of non-receptor tyrosine kinases by AT1R. Ushio-Fukai et al., 1998 (48).
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Genomic Organization
Mice and rats harbor two AT1R genes (Fig. 1.5), designated AT1AR and AT1BR
(55). Both the rat AT1AR and AT1BR genes are comprised of three exons (56-58). The
third exon of both sub-types encodes the entire coding region of the receptor. Coding
regions of these genes have 92% sequence identity at nucleotide level and 95% homology
at amino acid level (59). Both rAT1AR and rAT1BR exhibit similar ligand binding and
signal transduction properties.

However, the tissue distribution and transcriptional

regulation are different. While rAT1AR is predominantly expressed in the kidney, heart,
aorta, lung, liver, testis and brain, rAT1BR is the predominant sub-type in adrenal and
pituitary glands.
In contrast to rodents, although an AT1BR has been reported in humans (61), it is
widely accepted that only one gene for AT1R exists in humans. The presence of a single
gene for AT1R in humans has been validated by experiments performed in our lab (Fig.
1.5) (60). This difference in the number of genes between rodents and humans precludes
the possibility of using rodents as a model for studies of AT1R gene regulation in
humans.
The human AT1R gene consists of four exons and three introns (Fig. 1.6) (62).
The entire coding region and the 3′-untranslated region (UTR) of the AT1R is harbored
uninterrupted in exon 4. Interestingly, the four exons have been demonstrated to be
differentially spliced to form four distinct mature mRNAs (Fig. 1.7). These mRNAs
differ in their 5′-UTR depending on the exons present in the mRNA. All the splice
variants contain exons 1 and 4. The difference between the splice variants arise in the
presence of exon 2, 3 or both.
12
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Figure 1.5 Genomic southern blot.
Southern blot containing 8 µg of genomic DNA per lane from nine eukaryotic species. DNA was restricted
with Eco RI. Lanes 1-9 contain, in order, genomic DNA from human, monkey, rat, mouse, dog, cow,
rabbit, chicken and yeast. The zoo blot was probed with a random-prime labeled hAT1R fragment. Su et
al., 1996 (60).
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Exons 1 and 2 have an AUG start codon and an in-frame stop codon. However,
the start codon harbored in exon 1 is not in the proper Kozak context, an adenosine three
nucleotides upstream of AUG (76, 77), and does not lead to efficient translational
initiation. The splice variant containing exons 1 and 4 gives rise to 359 amino acid long
functional hAT1R and is the predominant form in most tissues that express hAT1R (63).
Translational initiation from exon 2 leads to premature termination and does not lead to
synthesis of a functional receptor. However, exon 3 has a start codon that is in-frame
with the start codon on exon 4. Translational initiation at this start codon generates a
functional receptor that has an additional 32 amino acids at the N-terminus (63).

hAT1R Polymorphisms
Single nucleotide polymorphisms (SNP) have been implicated in the
pathophysiology of various diseases. The AT1R gene has many SNPs. The genetic
analysis

of

hypertensive

subjects

with familial

susceptibility

identified

five

polymorphisms; T573C, A1062G, A1166C, G1517T and A1878G (64). While the first
two polymorphisms are in the coding region of the gene, the others are in the 3′-UTR. A
comparison of hypertensive and normotensive subjects showed a significant increase in
the allelic frequency of C at position 1166 in hypertensive subjects. However, a linkage
analysis did not provide any evidence of linkage in the sib pairs studied (65). The
association of A1166C to hypertension has been studied by various investigators (66-69).
The data from these studies suggest A1166C polymorphism is associated with an increase
in the sensitivity to Ang II in subjects with the CC allele (66, 68, 69). Several studies
have focused on this particular SNP since it was first shown to have correlation to
14
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Figure 1.6 Schematic representation of hAT1R gene.
Exons 1 and 2 harbor start and stop codons. Exon 3 harbors a start codon that is in frame with the start
codon found in exon 4. The entire hAT1R gene spans more than 60 kilobases.
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Figure 1.7 Schematic representation of hAT1R mRNA splice variants.
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2250 bp

hypertension.

However, the biochemical basis for this difference has not been

investigated. Pende et al. (70), in their study of binding of AU-rich element binding
factor 1 (AUF1) to hAT1R, did not observe any difference in the binding of AUF1 to the
wildtype or the mutant allele, but no studies have been carried out to investigate whether
the A Æ C transversion leads to a change in the hAT1R mRNA stability and alters the
cell surface receptor expression.

Regulation of hAT1R
The human AT1R plays a significant role in mediating physiological actions of
Ang II and the cell surface expression of the receptor is highly regulated. Ang II
stimulation of cells leads to a rapid desensitization of the receptor by phosphorylation
mediated by G-protein coupled receptor kinase (GRK). This is then followed by binding
of β-arrestins and clathrin adapter-2 (AP-2, Fig. 1.8) which are then targeted to clathrincoated pits (CCPs, 106, 107). In addition to mediating the interaction between the
complex and the CCPs, β-arrestins also recruits c-src to the complex which on
phosphorylation releases the AP-2 for recruitment into more complexes of the cell
surface receptor for internalization (107). This downregulation of the cell surface protein
prevents sustained activation of the receptor generating second messengers. Removal of
Ang II from the medium leads to externalization of the receptor, which then mediates the
transmembrane signaling of the extracellular ligands.

17

Figure 1.8 Schematic of AT1R receptor internalization.
Agonist stimulation of AT1R promotes the recruitment of a ternary complex containing c-Src, AP-2 and
ßarrestin. The complex would then be targeted to CCPs, and the presence of multiple receptor complexes in
addition to the recruitment of other endocytic proteins into the CCP would trigger the internalization of the
coated vesicle. AT1R, Angiotensin II type 1 receptor; A, agonist; AP-2, clathrin adaptor 2. Chagnovich and
Cohn, 1997 (107).

18

Transcriptional versus Post-transcriptional Regulation
The hAT1R gene transcription in unstimulated cells seems to be governed by the
TATA box. In H295R cell line, the basal transcription of hAT1R gene is initiated 24
nucleotides downstream of the TATA box and requires the transcription factors SP1 and
SP3 (78, 79). However, not much is known about the regulation of hAT1R transcription
in response to Ang II in humans. In rats, the transcription of AT1R has been shown to
decrease by 70 % after 4 hours of Ang II treatment (71). Epidermal growth factor (EGF),
basic fibroblast growth factor (bFGF) and platelet-derived growth factor-BB (PDGF-BB)
(72) have also been shown to decrease the transcription of AT1R gene by 28, 29 and 17%
respectively. In rat aortic VSMC, growth factors lead to a significant decrease in the
transcription and the mRNA stability is also greatly decreased (71). This suggests that
the downregulation of AT1R mRNA is both transcriptional and post-transcriptional. Ang
II-mediated downregulation is concentration and time dependent; the maximal
downregulation of mRNA occurs after four hours of Ang II treatment and the mRNA is
decreased by 70% of control (71).
The stability of mRNA plays a major role in the post-transcriptional regulation of
genes, as the mRNA turnover depends on both transcription and the degradation of the
gene transcripts. After partial hepatectomy, alteration of mRNA stability seems to be the
important post-transcriptional mechanism in gene regulation in the regenerating liver
(80). In addition to playing a major role in development, stability of mRNA is regulated
in response to hormones (81), growth factors (82) and is also subject to diurnal variation
(83).

19

Three general mechanisms govern the degradation of mRNA in eukaryotic
systems; (i) PolyA shortening leading to decapping of mRNA and subsequent 5′-3′
degradation, (ii) PolyA shortening, leading to the 3′-5′ degradation of the mRNA and (iii)
Non-polyA dependent, specific cleavage by endonucleolytic RNases.
The cis-elements that are involved in the stability of mRNA are 5′-cap, polyA,
stem-loop structures and in some cases, AU rich elements (ARE). Studies with various
mRNA showed that mRNA that have longer polyA tails have increased half-life (84).
PolyA-binding proteins (PABP) bind to the polyA tail which inhibits the deadenylation
and shortening of polyA in mRNAs and hence stabilizes the mRNA from undergoing
decapping and degradation (85). In contrast, histone mRNAs which do not a have polyA
tail, instead possess stem-loop structures in their 3′-UTR which prevent their degradation
by 3′-5′ exonuclease (86).

Similar to PABPs, cap-binding proteins are involved in

binding to the 5′-cap and stabilization of the gene transcripts, by inhibiting the decapping
enzyme and preventing the 5′-exonuclease activity.

Although AREs are generally

considered to destabilize mRNAs when present in their 3′-UTR, stimulation of cells with
mitogens has shown that some ARE-containing mRNAs are stabilized (87).
AREs have been known to be involved in the degradation of a large number of
mRNAs that belong to many different classes of mRNAs including immune regulators
(interleukins and interferons, 88, 89), proto-oncogenes (c-myc and c-fos, 88, 89) and
receptors (β-adrenergic receptor, 92). The destabilization of mRNAs harboring AREs are
mediated by the binding of various ARE-binding proteins, such as AUF1 (88), ELAV
(embryonic lethal, abnormal visual system, 89), TTP (Tristetraprolin, 90) and HuR
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(ELAV-like protein, 91). While AREs are always present in the 3′-UTR of the mRNA,
other elements that are present in the 5′-UTR and coding region of gene transcripts have
also been identified. c-myc and c-fos genes are known to harbor destabilizing elements
in their coding region (93, 94); however the nature of the decay determinant is not well
understood. The 5′-UTR of IL-2 (95) and chemokine KC (96) mRNAs contain JNKresponse element that targets them for degradation.
Studies on the stability of the AT1R mRNA have not been performed in humans;
however, studies in rats have shown that elements in the 3′-UTR as well as 5′-UTR may
be involved in the destabilization of AT1R mRNA. Studies using transcriptional and
translational inhibitors suggested that destabilization plays a major role in the
downregulation of AT1R mRNA (71).

Subsequent studies by the same research

laboratory showed that the 3′-UTR may be involved in the Ang II-mediated
destabilization of AT1R mRNA (97). Although Ang II does not cause a significant
increase in the levels of cAMP, cAMP mediated activation of PKA has been implicated
in the downregulation of AT1R mRNA (98, 99). Other studies have shown that the
cAMP-mediated downregulation of AT1R mRNA is dependent on elements present in the
5′-UTR (100). Recently, Nickenig et al. demonstrated that bases 2175-2195 in the
rAT1AR mRNA is involved in its destabilization (101). Further studies showed that
calreticulin binding to this region destabilized the mRNA and the phosphorylation of
calreticulin is essential for the protein-mRNA interaction (102). Since calreticulin does
not have any intrinsic RNase activity, the mechanism by which the AT1R mRNA is
targeted for degradation is not well known.
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mRNA stability is a critical regulator gene expression in addition to transcription and its
abnormal regulation can lead to various diseases. Higher levels of the mRNA could
result in increased levels of protein synthesis leading to change in the state of the cell. In
neuroblastoma, it has been demonstrated that in small neuroblastic cells the stability of
the n-myc mRNA is higher and the steady state levels of the mRNA and protein are
increased and is suspected to be the cause of the higher tumorigenicity of these cells
(103). The larger substrate adherent cells, do not exhibit increased stability of n-myc
mRNA and are not tumorigenic. α-thalassemia is another disease where the increase in
the stability of the mRNA results in abnormal pathology (104). The mutant globin
mRNA in the erythroid cells accumulate and represents over 95 % of total RNA. In
Fukuyama-type congenital muscular dystrophy, the retrotransposal insertion into the 3′UTR of the protein fukutin causes the abnormal change increasing the destabilization of
the mRNA leading to the disease (105).
Hence, understanding the Ang II-mediated downregulation of the AT1R mRNA in
humans is very important as AT1R signaling plays a major role in various physiological
processes. To better understand how the human AT1R is regulated, it is essential to
identify the means of transcriptional or post-transcriptional downregulation. We focused
our efforts on the 3′- and 5′- untranslated regions for their role in the Ang II-mediated
downregulation of the hAT1R mRNA. The identification of the RNA motifs on the
mRNA is very important. Studies were also conducted that determined if the regulation
also involves transcriptional control of the gene. The complete characterization of the
structural and biochemical aspects of the Ang II-mediated AT1R mRNA downregulation
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is important for understanding the actions of Ang II and its role in the pathophysiology of
hypertension, cardiac hypertrophy, coronary artery disease and atherosclerosis.
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CHAPTER 2

Analysis of hAT1R 3′-UTR, 5′-UTR and Promoter in
Ang II-mediated Regulation of hAT1R mRNA

INTRODUCTION

In general, expression of a gene can be regulated at various stages; transcription
of DNA into heteronuclear RNA (hnRNA), processing of the hnRNA to form mature
mRNA, its export from nucleus to the cytoplasm and stability of the mRNA in the
cytoplasm. The transcriptional regulation and mRNA stability have been well studied
and together account for most of the control of gene expression in all organisms. At the
transcriptional level, expression depends on the promoter sequences present at the 5′-end
of the gene. Except for constitutively active genes, basal level expression of most genes
requires the presence of a TATAA box 25 to 35 bases upstream of the transcription start
site (1). Transcription factor IID (TFIID) binds to the TATA box to activate transcription
of the genes by RNA polymerase II (2). In addition to the TATAA sequences, CCAAT
sequences present 70 to 80 nucleotides upstream of the transcription start site are ciselements that are also involved in the basal transcription of genes (3). Transcription
factors such as CCAAT-binding transcription factor and CCAAT-binding protein
mediate transcription of genes by interacting with the CCAAT box and RNA polymerase
II (4).
Regulation of transcription plays a vital role in the development of an organism
by altering the rate of transcription of genes at various stages. The transcriptional profile
of genes is altered during the various stages of development and also in response to
external stimuli such as hormones, cytokines, small molecules and cell-cell interactions.
The transcription of some genes may be increased while others are repressed depending
on the state of development or the stimuli.
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The AT1R expression can be regulated in a variety of ways; transcription of
mRNA, stability of the mRNA in the cytoplasm translation of mRNA into protein, cell
surface expression of the protein, desensitization and internalization of the receptor. The
regulation of the AT1R at the level of cell-surface expression is well understood; the
receptor is desensitized after binding its agonist, Ang II, and mediation of signal
transduction across the membrane by phosphorylation of the receptor by G proteincoupled receptor kinases (GRKs) (5, 6). Prolonged stimulation of the cells with Ang II
leads to internalization and sequestration of the cell surface receptor. This is mediated by
binding of β-arrestins and recruitment of the receptor to the clathrin-coated pits (CCPs)
(7, 8). However, not much is known about the regulation of the AT1R mRNA in humans.
The AT1R mRNA transcription and stability depends on the state of the cell. The
transcription and stability of the AT1R mRNA are known to change after activation with
various stimuli. In rats, growth factors such as epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF) and platelet-derived growth factor-BB (PDGF-BB) have
also been shown to decrease the transcription of rAT1R gene (9). In rat VSMCs, growth
factors lead to a significant decrease in transcription rates and rAT1R mRNA stability is
also greatly reduced. This suggests that the downregulation of AT1R mRNA is governed
both by transcriptional and post-transcriptional mechanisms.

In rats, the maximal

downregulation of mRNA occurs at four hours after Ang II treatment and the mRNA is
decreased by 70% of control (10). Lassegue et al. (10) have shown that the transcription
of the rAT1R is decreased by 50% after 4 h Ang II treatment. The other 20% decrease in
steady state mRNA is suggested to be due to post-transcriptional regulation of AT1R
mRNA.
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Recent studies have showed that AUUUUA sequences in the 3′-UTR are involved
in the degradation of β1-adrenegic receptor mRNA (11) and AT1AR mRNA in rat
VSMCs (12, 13).

Additionally, Nickenig et al. have identified the rat AUUUUA

sequence as the cis-element responsible for the Ang II-mediated degradation of rAT1AR
mRNA (12). They have also shown that phosphorylated calreticulin binds to the above
consensus sequence (13). However, the mechanism by which calreticulin leads to the
degradation of rAT1AR mRNA is not understood.
Studies by Wang et al. have shown that the Ang II-stimulated degradation of
rAT1AR mRNA is mediated through the protein kinase A dependent pathway (14, 15).
Also, Bird et al. have shown that protein kinase A, protein kinase C and Ca2+ pathways
are involved in the Ang II-mediated degradation of hAT1R mRNA (16, 17). They also
demonstrated that the Ang II effect was blocked by the presence of cycloheximide,
whereas the forskolin-dependent degradation of hAT1R mRNA was not blocked by
cycloheximide (16, 17). This suggests that both the protein kinase A and protein kinase
C pathways are involved in the Ang II-dependent degradation of hAT1R mRNA.
Taken together, most studies suggest that post-transcriptional regulation is the
most common mechanism by which the rAT1R is regulated. However, since rodents
harbor two AT1R genes, it can not be assumed that hAT1R expression will be regulated
by the same mechanism since the human genome harbors a single AT1R gene. Therefore,
the following study was initiated to determine whether Ang II mediated decrease in
hAT1R mRNA results from post-transcriptional or transcriptional mechanisms.
Interestingly, all of our experiments demonstrate that Ang II treatment does not induce
changes in hAT1R mRNA decay rates.

Nuclear run-on assays showed that the
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transcription of hAT1R gene is downregulated on Ang II stimulation. Therefore, we
conclude that in human adrenal carcinoma cells, Ang II mediates changes in AT1R
expression at the transcriptional level.
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MATERIALS AND METHODS

Materials
All common laboratory chemicals were purchased from Sigma (St. Louis, MO)
and Fisher Scientific (Pittsburg, PA). All enzymes used in cloning were obtained from
Fisher Scientific, Promega Corp. (Madison, WI) and Fermentas Inc. (Hanover, MD). T7
Sequenase Version 2.0 dGTP Reagent Kit was purchased from USB Corp. (Cleveland,
OH).

Cell Culture
The human adrenocortical carcinoma cells (H295R, American Type Culture
Collection [ATCC], Manassas, VA) were grown in 1:1 Dulbecco’s Modified Eagle
medium: Ham’s F12 mixture supplemented with 5% Nu-Serum (BD Biosciences,
Bedford, MA), 1% ITS+ premix (insulin, transferrin, selenium, linoleic acid and BSA,
BD Biosciences), 80 units/ml penicillin and 80 µg/ml streptomycin at 37°C in a tissue
culture incubator with 5% CO2 atmosphere.

RNA Isolation
RNA was isolated from H295R cells using Trizol reagent (Invitrogen
Corporation, Carlsbad, CA) according to manufacturer’s protocol. Briefly, the medium
was aspirated from the tissue culture dish and 300 µl of Trizol reagent was added. RNA
from the cell suspension was extracted by adding 60 µl of chloroform and precipitated
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with isopropanol. The RNA was washed with 75% ethanol and resuspended in RNasefree water.

Northern Blotting
10 µg of RNA was loaded per lane in a 1.1% agarose formaldehyde gel and
electrophoresed at 6 V/cm.

The RNA was then transferred to a nylon membrane

overnight by passive transfer with 10X SSC buffer. The blot was then washed with
DEPC-H2O. The membrane was prehybridized with Express-Hyb (Clontech, Palo Alto,
CA) hybridization solution for 30 minutes at 65°C. Radioactively labeled probe specific
for AT1R, GAPDH, β-globin or 3X-FLAG was then added to the membrane and rotated
for 1 hour at 65°C. The membrane was washed with 2X SSC/0.1% SDS buffer at room
temperature followed by two washes for 15 minutes in 0.2X SSC/0.1% SDS at 65°C.
The membrane was exposed to a phosphorimaging screen for four days. The quantitation
of the bands was done as described below.
AT1R and GAPDH probes were synthesized by random hexamer labeling. A 648
bp long AT1R coding region fragment, bases 211 to 858 of AT1R open reading frame
(ORF), was used as the template for AT1R probe synthesis. A 320 bp long GAPDH
coding region fragment, bases 305 to 624 of GAPDH ORF was used for GAPDH probe
synthesis. For random hexamer labeling, the Prime-a-Gene Labeling System (Promega)
was used to synthesize the probes according to the manufacturer’s protocol.
The 3X-FLAG and β-globin single-stranded DNA probes were synthesized by
asymmetric PCR according to Orrù et al (18). The 3X-FLAG template used for probe
synthesis was a 515 bp fragment obtained by Bam HI and Bst X1 digestion of p3XFLAG46

CMV-14, and the forward and reverse primers were 5′-GACTACAAAGACCATGACG
GTG-3′ and 5′-CTTGTCATCGTCATCCTTGTAGTCG-3′, respectively. The template
used for β-globin probe synthesis was a 126 bp fragment obtained by Xho I and Eco RI
digestion of pCI-glo vector, and the forward and reverse primers were 5′-CACTCCTCA
GGTGCAGGCTGC-3′ and 5′-GGGGCTTCATGATGTCCCCATAA-3′, respectively.
For asymmetric probe labeling, the 3XFLAG or β-globin was subjected to polymerase
chain reaction (PCR) using Taq polymerase (Invitrogen Corporation). 4 nM forward
primer and 100 nM reverse primer, described above, were added to the reaction and 10
cycles of amplification was performed with denaturation at 94°C for 30 seconds,
annealing at 50°C for 30 seconds and extension at 72°C for 30 seconds. To the above
reaction tube, 1.0 µl of 32P-dCTP and 0.3 µl of 100 µM of dGTP, dATP and dTTP was
added. 20 more cycles of amplification was performed with the cycling conditions as
before. The probes were purified using +STE-30 (Clontech Laboratories, Inc.) column
according to manufacturer’s instructions.

Phosphorimaging System
Quantitation of the gels and Northern blots was performed using the Storm 860
system (GE Healthcare, UK).

The radioactively-labeled blot was exposed to a

phosphorimaging screen and scanned in the Storm 860 scanner with a resolution of 200
microns. The scanning software used was Scanner Control Version 4.1, Build 2 (GE
Healthcare). The scanned image was then analyzed using ImageQuant Version 4.2a,
Build 13 (GE Healthcare).
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First Strand cDNA synthesis
2 µg of RNA was mixed with 1 µl of 10 mM dNTP mix and 1 µl of oligo(dT)
(500 µg/ml) or random hexamer (250 µg/ml) in a total volume of 12 µl. The mixture was
heated to 65°C for 5 minutes and quick chilled on ice for 2 minutes. 4 µl of 5X first
strand buffer, 2 µl of 0.1 µM DTT and 1 µl of SUPERase-In RNase inhibitor (Ambion,
Austin TX 78744) were added at 42°C [oligo(dT) primers] for 2 minutes. For random
hexamers, the 2 minutes incubation after addition of 5X first strand buffer, DTT and
SUPERase-In RNase inhibitor (Ambion) was performed at 25°C.

Then 1 µl of

Superscript II Reverse Transcriptase (Invitrogen) was added, mixed gently and incubated
at 42°C for 50 minutes. To inactivate the reaction, the mixture was heated to 70°C for 15
minutes.

3′-Rapid Amplification of cDNA Ends (3′-RACE)
RNA was isolated from H295R cells utilizing Trizol reagent as described above.
The 3′-RACE was performed using the FirstChoice RLM-RACE Kit (Ambion) according
to the manufacturer’s protocol. Briefly, 2 µg of RNA was reverse transcribed with
MMLV Reverse Transcriptase using the 3′-RACE adapter.

The cDNA was then

amplified in two successive rounds of PCR; first with the 3′-RACE outer primer and
hAT1R specific primer; then the first reaction was used as a template to amplify using the
second primer pair, 3′-Inner primer and another hAT1R specific primer.

The PCR

product after the second round was subcloned into the pCR 2.1™ vector (Invitrogen) and
sequenced to determine the polyadenylation site at the 3′-end of hAT1R 3′-UTR.
48

In Vitro Transcription
The full length hAT1R 3′-UTR (886 bp) was PCR amplified and subcloned into
the pCR 3.1™ vector (Invitrogen). The clone was sequenced to confirm the proper
orientation of the insert downstream of the T7 promoter and for the fidelity of the
sequence. The resulting construct was then linearized 3′ of the insert using the restriction
endonuclease, Xba I. The linearized plasmid was purified using TaKARa spin columns
(TaKaRa, Madison, WI). 1 µl of the linearized plasmid was used as template for the in
vitro transcription reaction using T7 RNA polymerase (Ambion) according to the
manufacturer’s protocol. Labeled RNA transcripts were produced by adding α-32P-UTP
(3000 Ci/mmol) (PerkinElmer LAS, Inc., Shelton, CT) to the reaction.

Cytoplasmic Extracts
The cytoplasmic extracts were prepared according to Lazarov et al. (19). Briefly,
H295R cells were washed with ice-cold phosphate buffered saline (PBS), harvested by
scraping and pelleted at 3000 rpm for 4 minutes at 4°C. The cell pellet was resuspended
in 200 µl of cold homogenization buffer (10 mM Tris-HCl, pH 7.8, 2 mM MgCl2, 10 mM
KCl, 20% glycerol, 0.5 mM DTT, 100 µg/ml PMSF, 5 µg/ml aprotinin and 1 mM
Na3VO4). The cells were then lysed with 20 strokes in a Dounce homogenizer using a
“loose” piston. The lysate was then centrifuged at 8000 rpm for 5 minutes at 4°C. The
supernatant (cytoplasmic extract) was stored at -20°C.
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In vitro Cell-free RNA Degradation Assay
The RNA degradation assay was performed according to a previously described
protocol (19). Briefly, 100 ng of RNA transcripts were mixed with incubation buffer (10
mM Tris-HCl, pH 7.6, 40 mM KCl, 3mM MgCl2, 5% glycerol, 0.5 mM DTT), 1 µg
tRNA and 1 µg cytoplasmic extract in a total volume of 25 µl on ice. The reaction
mixture was then incubated at 37°C. 5 µl aliquots were withdrawn at 0, 5, 10, 15, 30 and
45 minutes and added to 145 µl of stop solution (10 mM Tris-HCl, pH 7.6, 0.2% SDS,
0.2% NP-40 and 5 mM MgSO4). The RNA was extracted with phenol-chloroform and
precipitated with 10 µg tRNA, 20 µl 3M NaOAc and 400 µl 100% EtOH.

After

centrifugation the RNA was washed with 75% EtOH and resuspended in 5 µl of DEPCH2O. The RNA was separated by electrophoresis in a 1.5% agarose-formaldehyde gel.
The gel was dried at 65°C for 90 minutes and exposed to phosphorimaging screen and
quantitated.

Luciferase Reporter Constructs
pGL3 promoter plasmid was utilized to generate the firefly luciferase fusion
constructs with the 5′- and 3′-UTRs. Sequence that encodes the SV40 polyA signal in the
pGL3 promoter was removed by digestion with Xba I and Bam HI, the ends were filled-in
and religated. This new plasmid that retained a Bam HI restriction site was designated
pGLPRO. The 886, 378 and 337 bp fragments were cloned into the Bam HI site 3′ to the
luciferase after the fragments were isolated from pCR 2.1-3′-RACE clones by restriction
digestion with Bam HI and designated pGLPRO-886, pGLPRO-378 and pGLPRO-337,
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respectively. The 5′-UTR inserts were isolated from a pCR 2.1 clone by digestion with
Eco RI and filled-in to make blunt ends. The above insert was then blunt end-ligated into
the pGLPRO or pGLPRO-886 clone that was digested with Nco I, filled-in to form a
blunt end and the resulting clones were designated pGLPRO-5′-UTR and pGLPRO-5′UTR-3′-UTR, respectively.

β-globin Constructs
pCI-glo construct was a kind gift from Dr. Medcalf (Monash University, Victoria,
Australia). The pCI-glo plasmid was digested with Xho I and filled in to form blunt end.
The 886, 378 and 337 bp fragments were isolated from pCR 2.1-3′-RACE clones by
restriction digestion with Eco RI, filled-in, cloned into the pCI-glo and designated pCIglo-886, pCI-glo-378 and pCI-glo-337, respectively. The orientation and fidelity of the
inserts in all the constructs were confirmed by sequencing.

Transfection of Plasmids
Transfection of plasmids into H295R cells in six-well plates were carried out
using Lipofectamine-Plus reagent (Invitrogen) according to the manufacturer’s protocol.
Briefly, 2 µg of DNA was incubated with 100 µl of serum-free 1:1 DMEM/F12 medium
and 6 µl PLUS reagent for 15 minutes at room temperature. 3 µl of Lipofectamine
reagent prediluted in serum-free 1:1 DMEM/F12 medium was then added and the
mixture was incubated for 15 minutes. The DNA-complexes were then added to cells
with 800 µl serum-free 1:1 DMEM/F12 medium and incubated in a cell culture incubator
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at 37°C with 5% CO2 for 4 hours. The medium on the cells was then replaced with
serum-free 1:1 DMEM/F12 medium.

Dual Luciferase Assay
The dual luciferase assay was performed using the Dual Luciferase Reporter
Assay System (Promega) according to manufacturer’s protocol. Briefly, the growth
medium was aspirated and the cells were washed once with PBS. 300 µl of 1X passive
lysis buffer was added to the cells, incubated with shaking at room temperature for 15
minutes, centrifuged and the lysate was then transferred to a new centrifuge tube. 20 µl
of the lysate was transferred into a luminometer tube, 20 µl of the Luciferase Assay
Reagent II was added to the lysate, vortexed and the light intensity was measured in a
luminometer for 10 seconds. This was then followed by the addition of 20 µl of Stop &
Glo reagent, vortexed and the light intensity was measured again in the luminometer for
10 seconds. The first measurement of light intensity shows the firefly luciferase activity
and the second shows Renilla luciferase activity.

Actinomycin D Inhibition Assay
H295R cells grown in 6-well plates were serum starved for 36 hours. The cells
were then pretreated with 2.5 µg/ml actinomycin D for 2 hours. This was then followed
by stimulation of cells with Ang II for 0, 1, 2, 4 and 6 hours in addition to Actinomycin
D. The control cells were continually treated with actinomycin D for 0, 1, 2, 4 and 6
hours. The RNA was isolated from the cells and cDNA synthesized using oligodT
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according to protocols described above. The cDNA was then quantitated using real time
PCR as described below.

Real-Time Polymerase Chain Reaction
The real time PCR was conducted using LightCycler (Roche Diagnostics
Corporation, Indianapolis, IN). The primers used for the amplification of hAT1R were
forward, 5′-CCATGTTTTGAGGTTGAGTGACATG-3′ and reverse, 5′-C AGGCTAGG
GAGATTGCATTTCTG-3′. The forward and reverse primers used for GAPDH were 5′CACCACCATGGAGAAGGCTGGG-3′ and 5′-AGGGATGATGTTCT GGAGAGCCC3′, respectively. The real time PCR reactions were performed using SYBR Green Taq
ReadyMix for Quantitative PCR, Capillary Formulation (Sigma) according to the
manufacturer’s protocol with 300 nM primers (final concentration).

The initial

denaturation was at 94°C for 15 seconds. The cycling parameters were 94°C for 5
seconds, 65°C for 3 seconds and 72°C for 20 seconds. The fluorescence was measured at
the end of the extension. After 40 cycles of the above cycling conditions, the DNA was
denatured slowly and the fluorescence was measured continuously which can be used to
analyze the amplicons for specific/non-specific amplification. A GAPDH standard curve
was created with known quantity of GAPDH template and the test samples were
quantitated using the external standard curve. The hAT1R was quantitated against the
GAPDH standard curve and normalized to GAPDH.
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Nuclear Run-On Assay
The nuclei were prepared from H295R cells as follows (20). H295R cells were
washed with cold PBS, harvested by scraping and pelleted at 1500 rpm for 10 minutes at
4°C. The pellet was washed once with ice-cold PBS and pelleted as before. The cell
pellet was resuspended in 5 ml of cold NP-40 lysis buffer (10 mM Tris-HCl, pH 7.4, 10
mM NaCl, 3 mM MgCl2, 0.5% NP-40) and incubated for 5 minutes on ice to lyse the
plasma membranes. The nuclei were pelleted in a clinical centrifuge at 100 rpm for 10
minutes at 4°C. The supernatant was discarded and the nuclear pellet was resuspended in
500 µl of nuclear freezing buffer (50 mM Tris-HCl, pH 8.3, 40% v/v glycerol, 5 mM
MgCl2, 0.1 mM EDTA). The nuclear pellet was aliquoted and stored at -80°C.
Biotin labeling of the nascent transcripts was performed as follows according to
Carey (20) with modifications described below. The frozen nuclei were thawed on ice
and the contents of the tube were mixed. 240 µl of the nuclei was added to 60 µl of 5X
run-on buffer (25 mM Tris-HCl, pH 8.0, 12.5 mM MgCl2, 750 mM KCl, 1.25 mM ATP,
1.25 mM GTP, 1.25 mM CTP, 1.25 mM biotin-16-UTP [Roche Diagnostics
Corporation]). The reaction mixture was incubated for 30 minutes at 29°C. 2.5 µl of 1M
CaCl2 and 5 µl of RNase-free DNase was added and incubated at 30°C for 10 minutes.
RNA was isolated using Trizol reagent (Invitrogen) according to the
manufacturer’s protocol with some modifications as follows. 700 µl of the Trizol reagent
was added to the reaction mixture and mixed by pipetting up and down. 200 µl of
chloroform was added and shaken vigorously for 15 seconds. After 3 minutes the tubes
were centrifuged at 12,000xg for 15 minutes. The RNA was then precipitated with 500

54

µl isopropanol followed by a wash with 75% RNase-free ethanol. The RNA was airdried and resuspended in 50 µl of DEPC-H2O.
The biotin-labeled RNA was purified using Dynabeads M-280 (Dynal Biotech
ASA, Oslo, Norway) according to Patrone et al. (21) as follows. 50 µl of Dynabeads M280 resuspended in binding buffer (10 mM Tris-HCl, pH 7.5, 1 mM EDTA, 2 M NaCl)
was mixed with an equal volume of run-on RNA, 1 µl SUPERase-In RNase inhibitor
(Ambion) and incubated for 20 minutes at 42°C and then for 2 hours at room
temperature. Beads were separated using a magnetic apparatus and washed twice with
500 µl 15% formamide in 2X SSC for 15 minutes. The beads were then resuspended in
30 µl DEPC-H2O and stored at -20°C.
First strand cDNA was synthesized from 10 µl of run-on RNA using random
hexamer primers as described above. 1.0 µl of the cDNA was used for quantitation of
hAT1R and GAPDH using real-time PCR as described above.

hAT1R levels were

normalized to GAPDH.

Promoter Assay
The -1003 to +39 bp promoter sequence was PCR amplified and subcloned into
Sma I site of the phRG-B plasmid, a Renilla luciferase reporter plasmid. The construct
was designated phRG-B-1003. A construct harbouring a longer promoter region, -2882
to +5 was also constructed which was designated phRG-b-2882. The orientation and
fidelity of the insert was confirmed by sequencing. The construct was transfected into
H295R cells as described above and serum starved for 48 hours. The cells were then
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treated with Ang II for various periods, lysed and the luciferase activities were measured
using dual luciferase assay kit (Promega) according to the manufacturer’s protocol.

NF-κB Inhibition Assays
H295R cells grown in 6-well plates were serum starved for 36 hours. The cells
were then pretreated with 20 µM BAY 11-7082, an inhibitor of IκB kinase α, for 1 hour.
This was then followed by stimulation of cells with Ang II for 4 hours in addition to
BAY 11-7082. The control cells were treated with BAY 11-7082 or EtOH for 5 hours.
Additional control cells were treated with vehicle or 100 nM Ang II for 4 hours. The
RNA was isolated from the cells and cDNA synthesized using oligo(dT) and the cDNA
was then quantitated using real time PCR as described above.

Histone Deacetylase (HDAC) Inhibition Assay
H295R cells grown in 6-well plates were serum starved for 36 hours. The cells
were then pretreated with 400 nM Trichostatin A (TSA), an inhibitor of histone
deacetylases (HDACs), for 1 hour. This was then followed by stimulation of cells with
Ang II for 4 hours in addition to TSA. The control cells were treated with TSA or EtOH
for 5 hours. Additional control cells were treated with vehicle or 100 nM Ang II for 4
hours. The RNA was isolated from the cells and cDNA synthesized using oligo(dT) and
the cDNA was then quantitated using real time PCR as described above.
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RESULTS
Ang II-mediated Regulation of hAT1R mRNA in H295R Cell Line
To determine if Ang II regulates the hAT1R steady state mRNA level in H295R
cells, Ang II treatment studies were performed. H295R cells grown in tissue culture
dishes were treated with Ang II and the hAT1R mRNA level was followed over time.
hAT1R mRNA was found to be regulated by Ang II. In comparison to vehicle treated
cells, Ang II caused a significant downregulation of hAT1R mRNA in H295R cell line
(Fig. 2.1). hAT1R mRNA was downregulated by 70% in cells treated with Ang II for
four hours compared to untreated cells. The mRNA levels remained at 30% of untreated
cells for up to six hours of Ang II treatment.

Effect of Protein Translation in Ang II-mediated hAT1R Downregulation
To determine whether protein translation is required for the downregulation of
hAT1R, translational inhibitor cycloheximide was used. Experiments were performed
with cycloheximide (CHX) in the presence or absence of Ang II. These experiments
showed that protein translation is required for the Ang II-dependent downregulation of
hAT1R mRNA (Fig. 2.2). In addition, treatment of cells with phorbol 12-myristate 13acetate (PMA) showed that the downregulation of hAT1R mRNA by Ang II is mediated
by signaling pathways downstream of PKC.
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Figure 2.1 Ang II-dependent downregulation of hAT1R in H295R cells.
H295R cells were treated with either vehicle or 100 nM Ang II for 0, 1, 2, 4, and 6 hours. 10 µg of RNA
was separated by electrophoresis, and transferred to Nytran (Schleicher and Schuell, Keene, NH)
membrane and hybridized to cDNA probe for AT1R and quantitated by phosphorimaging. The data were
normalized to GAPDH expression. A. Representative autoradiogram of the Northern assay. B. Graphical
representation of the normalized data. Data are mean ± S.D. from four independent experiments.
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Figure 2.2 Ang II-dependent downregulation of hAT1R in H295R cells.
H295R cells were treated with vehicle, 100 nM Ang II, 150 nM PMA, 35 µM CHX or CHX/Ang II for 4
hours. 10 µg of RNA was separated by electrophoresis, and transferred to Nytran (Schleicher and Schuell,
Keene, NH) membrane and hybridized to cDNA probe for AT1R and quantitated by phosphorimaging. The
data were normalized to GAPDH expression. A. Representative autoradiogram of the Northern assay. B.
Graphical representation of the normalized data. Data are mean ± S.D. from three independent
experiments.
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Analysis of hAT1R mRNA 3′-UTR
The hAT1R mRNA 3′-UTR was analyzed to determine the presence of consensus
sequences responsible for transcription termination and polyadenylation in hAT1R
mRNA. Sequence analysis revealed a consensus polyadenylation signal, AAUAAA, at
868 bp from the stop codon (Fig. 2.3). A semi-consensus polyadenylation signal which
leads to a less efficient polyadenylation, AUUAAA, is also present 354 bp downstream
from the stop codon. The sequence analysis also showed the presence of three AUUUA
sequences (Class I ARE, 22) at 343 bp, 699 bp and 857 bp that are known to confer
instability to mRNAs. Additionally, this analysis found two AUUUUA sequences (273
bp and 877 bp, Fig. 2.3), which have recently been shown to be involved in the
degradation of β1-adrenegic receptor mRNA (11) and rAT1AR mRNA in rat VSMCs
(13). Comparison of the rAT1R 3′-UTR mRNA sequence and the distal AUUUUA
present in the hAT1R 3′-UTR mRNA sequence shows that they are highly homologous
(Fig. 2.4), suggesting that the AUUUUA sequence in the 3′-UTR may play a role in the
degradation of the hAT1R mRNA. In recent studies Nickenig et al. (12) have identified
that the rat AUUUUA sequence (Fig. 2.4) as the cis-element responsible for the Ang IImediated degradation of rAT1AR mRNA. They have also shown that phosphorylated
calreticulin binds to the above consensus sequence. However, the mechanism by which
calreticulin leads to the degradation of rAT1AR mRNA is not understood.
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CUCAAACCUU UCAACAAAAA UGAGCACGCU UUCCUACCGC CCCUCAGAUA
AUGUAAGCUC AUCCACCAAG AAGCCUGCAC CAUGUUUUGA GGUUGAGUGA
1 CAUGUUCGAA ACCUGUCCAU AAAGUAAUUU UGUGAAAGAA GGAGCAAGAG
51 AACAUUCCUC UGCAGCACUU CACUACCAAA UGAGCCUUAG CUACUUUUCA
101 GAAUUGAAGG AGAAAAUGCA UUAUGUGGAC UGAACCGACU UUUCUAAAGC
151 UCUGAACAAA AGCUUUUCUU UCCUUUUGCA ACAAGACAAA GCAAAGCCAC
201 AUUUUGCAUU AGACAGAUGA CGGCUGCUCG AAGAACAAUG UCAGAAACUC
251 GAUGAAUGUG UUGAUUUGAG AAAUUUUACU GACAGAAAUG CAAUCUCCCU
301 AGCCUGCUUU UGUCCUGUUA UUUUUUAUUU CCACAUAAAG GUAUUUAGAA
351 UAUAUUAAAU CGUUAGAGGA GCAACAGGAG AUGAGAGUUC CAGAUUGUUC
401 UGUCCAGUUU CCAAAGGGC.A GUAAAGUUUU CGUGCCGGUU UUCAGCUAUU
451 AGCAACUGUG CUACACUUGC ACCUGGUACU GCACAUUUUG UACAAAGAUA
501 UGCUAAGCAG UAGUCGUCAA GUUGCAGAUC UUUUUGUGAA AUUCAACCUG
551 UGUCUUAUAG GUUUACACUG CCAAAACAAU GCCCGUAAGA UGGCUUAUUU
601 GUAUAAUGGU GUUACUAAAG UCACAUAUAA AAGUUAAACU ACUUGUAAAG
651 GUGCUGCACU GGUCCCAAGU AGUAGUGUCU UCCUAGUAUA UUAGUUUGAU
701 UUAAUAUCUG AGAAGUGUAU AUAGUUUGUG GUAAAAAGAU UAUAUAUCAU
751 AAAGUAUGCC UUCCUGUUUA AAAAAAGUAU AUAUUCUACA CAUAUAUAUA
801 UAUGUAUAUC UAUAUCUCUA AACUGCUGUU AAUUGAUUAA AAUCUGGCAA
851 AGUUAUAUUU ACUUUAAAAU AAAAUAAUUU UAUUGCAAUG UAUUU
Figure 2.3 The sequence of hAT1R mRNA 3′-UTR.
The arrows indicate the two polyadenylation sites. Red letters indicate the consensus polyadenylation
signal. Yellow letters indicate the semi-consensus polyadenylation signal. Blue letters indicate the
AUUUA ARE elements and purple letters indicate the AUUUUA ARE elements.
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rAT1AR -

5′-AAAGUAAUUUUAUUGUAAUGU-3′

hAT1R -

5′-AAAAUAAUUUUAUUGC-3′

Figure 2.4. Comparison of rat and human AUUUUA sequences.
The AU-rich region in rAT1AR spans 825 bp to 845 bp in the 3′-UTR. The AU-rich region in hAT1R spans
871 bp to 886 bp in the 3′-UTR.
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3′-Rapid Amplification of cDNA Ends
Since the analysis of hAT1R gene showed that it harbors a sequence that is
homologous to the destabilization sequence identified in rAT1AR mRNA, 3′-RACE
experiment was performed to determine the length of the 3′-UTR and to investigate the
presence of alternate polyadenylation sites in the hAT1R mRNA. 3′-RACE experiments
showed that the majority (~90%) of the hAT1R mRNAs were polyadenylated at 886 bp
downstream from the translation stop site (Fig. 2.3). This polyadenylation site was 18 bp
downstream of the consensus polyA signal. About 5% of mRNAs were polyadenylated
at 378 bp downstream of the translational stop site which was 24 bp downstream of the
semi-consensus polyA signal. The remaining hAT1R mRNAs were polyadenylated at
306 and 891 bp downstream from the stop codon. Most of the hAT1R mRNAs include
the AUUUUA sequence that has high homology to the rAT1AR destabilization sequence.
This suggests that the downregulation of hAT1R mRNA may be mediated by
degradation.

In vitro Cell-free RNA Degradation Assay
To determine whether the 3′-UTR may be involved in the degradation of the hAT1R
mRNA, an in vitro cell-free assay system was utilized. The full-length hAT1R mRNA 3′UTR was generated by in vitro transcription. The rate of degradation of the RNA was
observed in the presence of cytoplasmic extract isolated from H295R cells treated with
Ang II for 0, 1, 2 and 4 hours. The rate of degradation of the hAT1R mRNA treated with
the various cytoplasmic extracts did not differ significantly (Fig. 2.5).

The
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Figure 2.5 In vitro RNA degradation assay.
In vitro transcribed full length hAT1R 3′-UTR RNA was incubated with cell free cytoplasmic extract
isolated from H295R cells treated with Ang II for the indicated time. The degradation was followed by
running aliquots withdrawn at 0, 5, 10, 15, 30 and 45 minutes of incubation. The purified RNA was
separated on a gel, exposed to a phosphorimaging screen and quantitated using phosphorimaging system.
A. Representative gel. B. Data quantitated using ImageQuant Software. Data are mean ± S.D. from four
independent experiments.

64

half-life of the 3′-UTR in the degradation assay was 12 minutes. These results suggest
that hAT1R mRNA downregulation may not be mediated by its 3′-UTR.

hAT1R 3′-UTR Deletion-Luciferase Reporter Assay
The half-life of the 3′UTR is much shorter than that observed for mRNAs in
Northern assays. To validate the results from the in vitro degradation assays, a transient
transfection experiment was performed utilizing the fusion constructs of the firefly
luciferase open reading frame with the full length hAT1R mRNA 3′-UTR, and various 3′UTR deletions (Fig. 2.6). 48 hours post-transfection the cells were treated with vehicle
or Ang II for four hours, since downregulation of hAT1R was maximal after four hours of
Ang II treatment. The luciferase activity of the Ang II treated cells was not significantly
downregulated in any of the fusion constructs harboring the 3′-UTR (Fig. 2.7). The
luciferase activity of the constructs harboring the full length 3′-UTR and the distal 3′UTR was marginally increased after Ang II treatment.

hAT1R 3′-UTR Deletion-β-globin Reporter Assay
The luciferase assay determines the protein activity rather than estimating the mRNA and
the luciferase mRNA has a short half-life. Therefore, to examine whether the results
from the luciferase assay can be validated at the mRNA level, the β-globin reporter
system was utilized. β-globin has a longer half-life and hence the destabilization of its
mRNA, fused to hAT1R 3′-UTR, in the presence Ang II would be significantly different
compared to that treated with vehicle only.

β-globin fusion constructs with the
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Figure 2.6 Schematic representation of luciferase reporter constructs.
Various 3′-UTR deletions were fused downstream of firefly luciferase ORF in pGLPRO vector to generate
the chimeric constructs. 886 bp full-length 3′-UTR, proximal 378 bp and distal 337 bp were PCR
amplified and ligated into the pGLPRO vector at Bam HI site present downstream from the stop codon.
These fusion constructs were designated pGLPRO-886, pGLPRO-378 and pGLPRO-337, respectively.
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Figure 2.7 Luciferase assay of 3′-UTR fusion constructs.
H295R cells were transfected with fusion constructs of firefly luciferase with various 3′-UTR deletions.
pGLPRO is pGL3 promoter vector from which the SV40 polyA signal region is deleted. pGLPRO-886
harbors the full length (886 bp) hAT1R 3′-UTR inserted downstream from the luciferase gene. pGLPRO378 and pGLPRO-337 harbor the proximal 378 and distal 337 bp regions of hAT1R 3′-UTR, respectively.
48 hours post-transfection the cells were lysed and luciferase activities were measured by dual luciferase
assay. Data are mean ± S.D. from three independent experiments.
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various 3′-UTR were generated and transiently transfected into H295R cells.

For

normalization of transfection efficiency, a calreticulin-3XFLAG fusion construct was
generated and cotransfected with the 3′-UTR fusion constructs. The cells were treated
with Ang II for four hours and the hAT1R mRNA was quantitated by Northern blotting
(Fig. 2.8 A). The results show that Ang II does not downregulate the β-globin fused to
any of the hAT1R 3′-UTRs (Fig. 2.8 B) but leads to the stabilization of β-globin mRNA
by 50%.

5′- and 3′-UTR on Luciferase Stability
Current literature suggests that both the 5′-UTR and the 3′-UTR are essential for
the translation of mRNA. The 5′- and the 3′-UTR together form a circular mRNA by the
interactions of PABP, bound to polyA, and eIF4E, bound to the 5′-cap with eIF4G (23,
24). Hence, 3′-UTR may not be sufficient to cause the Ang II-mediated degradation of
hAT1R mRNA and the 5′-UTR may be essential in addition to the 3′-UTR. To determine
whether the 5′-UTR may be involved in the Ang II-mediated degradation along with 3′UTR, 5′-UTR of hAT1R was fused to the 5′ of the firefly luciferase gene in the pGLPRO
and pGLPRO-3′UTR plasmids. The results from the luciferase assay of the transiently
transfected H295R cells show that there is a significant increase in the luciferase activity
in cells treated with Ang II compared to vehicle treated cells (Fig. 2.9).
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Figure 2.8 Northern blot of cells transfected with β-globin 3′-UTR fusion constructs.
H295R cells were transfected with fusion constructs of β-globin with various 3′-UTR deletions. pCI-glo is
a β-globin vector. pCI-glo -886 harbors the full length (886 bp) hAT1R 3′-UTR inserted downstream from
the luciferase gene. pCI-glo -378 and pCI-glo -337 harbor the proximal 378 and distal 337 bp regions of
hAT1R 3′-UTR, respectively. The cells were treated with 100 nM Ang for 4 hours. Control cells were
treated with vehicle only. The RNA was isolated, blotted on nylon membrane and probed for β-globin. For
normalization, calreticulin-3XFLAG construct was cotransfected. A. Representative Northern blot. B.
Normalized data showing β-globin expression. Data are mean ± S.D. from three independent experiments.
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Figure 2.9 Luciferase assay of 5′- and 3′-UTR fusion constructs.
H295R cells were transfected with the various 5′- and 3′-UTR fusion constructs. 48 hours post-transfection
the cells were lysed, luciferase activity measured and total protein was quantitated. The luciferase values
were normalizaed to total protein. Data are mean ± S.D. from three independent experiments.
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In vivo Transcriptional Inhibitor Assay
All of the above experiments imply that the downregulation of the hAT1R mRNA
may not be mediated by its 5′-UTR or 3′-UTR.

To determine whether any post-

transcriptional mechanisms are involved in the downregulation of hAT1R mRNA,
transcriptional inhibitors were utilized to minimize the effect of transcription.
Actinomycin D was used to block all transcription in the cells and any difference in the
rate of hAT1R mRNA would be attributed to the degradation. The data from Fig. 2.10
suggest that in the presence of transcriptional inhibitor, the rate of degradation of hAT1R
mRNA is not significantly different between Ang II-treated and vehicle-treated cells.

Nuclear Run-On Assay
To examine whether the Ang II-mediated downregulation of the hAT1R mRNA
steady state levels is due to transcriptional inhibition, nuclear run-on assay was
performed. Nuclear run-on assay involves the transcriptional pausing by chilling of the
cells, isolation of the nuclei and synthesis of nascent transcripts with simultaneous
labeling. The nascent transcripts are then quantitated. The run-on assay was performed
with H295R cells that were treated with Ang II for 0, 1 and 2 hours. The results from the
assay show a significant decrease in the nascent transcript synthesis in H295R cells
treated with Ang II for 1 and 2 hours (Fig. 2.11).
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Figure 2.10 Actinomycin D inhibition assay.
H295R cells were pretreated with actinomycin D (2.5 µg/ml) for 2 hours. The samples were in addition
treated with 100 nM Ang II for 0, 1 2, 4 and 6 hours. Control cells were treated with actinomycin D alone
for similar time. RNA was isolated, reverse transcribed and cDNA was quantitated by real time PCR. A.
Quantification curves from real time-PCR analysis. B. Graphical representation of hAT1R normalized to
GAPDH. Data are mean ± S.D. from three independent experiments.
72

A.

B.

120

% of untreated

100
80
60
40
20
0
0

1

2

Time, h
Figure 2.11 Nuclear run-on assay.
H295R cells were treated with 100 nM Ang II for the 0, 1 and 2 hours. The nuclei were isolated, run-on
transcripts were synthesized and labeled with biotin-UTP. The transcripts were then purified and cDNA
was synthesized using random hexamer primers. hAT1R and GAPDH were quantitated by real time PCR
as described in Material and Methods. A. Quantification curves from real time-PCR analysis. B. Graphical
representation of hAT1R normalized to GAPDH. Data are mean ± S.D. from four independent
experiments.
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Promoter Assay
To validate the results observed using the nuclear run-on assay, promoter activity
assay was performed. While pGL3 basic is commonly used for promoter assays, we
observed that luciferase activity of cells transfected with pGL3 basic plasmid were
increased upon stimulation with Ang II (Fig. 2.12A). Hence, phRG-B plasmid was
utilized to generate the hAT1R promoter constructs.

The -1003 to +39 bp hAT1R

promoter was subcloned upstream of Renilla luciferase gene in the phRG-B plasmid and
utilized for the promoter assays. The data shows a small decrease in the luciferase
activity in cells transfected with the promoter fusion construct (Fig. 2.12B). However, a
similar decrease is also seen in control cells transfected with the phRG-B plasmid that
does not contain any promoter sequence. Promoter assay utilizing the promoter fusion
construct phRG-B-2882 was also performed to determine whether the Ang II-responsive
cis-element may be present more than 1000 bp upstream of the transcriptional start site.
To eliminate the effect of the cotransfected pGL3 Basic vector, the data were normalized
to the total protein content of the cells. Fig. 2.13 shows that there is no significant Ang II
dependent decrease in the luciferase activity compared to untreated cells.

NF-κB Inhibition Assay
The transcription factor NF-κB has been known to be activated in response to
Ang II.

Activation of IκB kinase (IKK) leads to phosphorylation of IκB and its

degradation results in release of active NF-κB. BAY 11-7082 is an inhibitor of IKK and
prevents the activation of NF-κB.
transcriptional
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To examine whether the Ang II-mediated
inhibition
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Figure 2.12 1003 bp AT1R promoter activity assay.
A. H295R cells were cotransfected with the pGL3 Basic and pRL-CMV plasmids. 48 hours posttransfection the cells were treated with vehicle or 100 nM Ang II for 4 hours, lysed and luciferase activities
were measured by dual luciferase assay. B. H295R cells were cotransfected with the phRG-B or phRG-B1003 constructs. 48 hours post-transfection the cells were treated with 100 nM Ang II for various period of
time, lysed and luciferase activities were measured by dual luciferase assay. Data are mean ± S.D. from
three independent experiments.
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Figure 2.13 2882 bp promoter region does not lead to significant Ang II dependent downregulation of
Renilla luciferase.
H295R cells were transfected with the phRG-B-2882 construct. 48 hours post-transfection the cells were
treated with 100 nM Ang II for various period of time, lysed and luciferase activity was measured by
luciferase assay. The luciferase data was normalized to the total protein. Data are mean ± S.D. from three
independent experiments.
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6

of hAT1R is mediated by NF-κB, cells were pretreated with BAY 11-7082 for 1 hour.
This was then followed by Ang II treatment while control cells were not treated with Ang
II. The results from the NF-κB inhibition studies show that pretreatment of cells with
BAY 11-7082 does not abrogate the Ang II-mediated downregulation of hAT1R mRNA
(Fig. 2.14).

HDAC Inhibition Assay
The structure of chromatin plays a major role in the activation and repression of
transcription of various genes. The structure of the chromatin depends on the state of
histone acetylation; acetylation of histones leads to transcriptional activation and
deacetylation results in repression. HDACs are enzymes involved in the deacetylation of
histones and their activation leads to repression of gene expression.

To determine

whether HDACs play a role in the Ang II-mediated transcriptional inhibition, TSA, an
inhibitor of HDACs was utilized. H295R cells were pretreated with 400 nM TSA before
addition of Ang II; control cells were incubated for 5 hours with TSA. The data from the
HDAC inhibition experiment shows that TSA pretreatment does not alter the Ang IIdependent downregulation of hAT1R mRNA (Fig. 2.15).
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Figure 2.14 Inhibition of NF-κB does not suppress Ang II-dependent downregulation of hAT1R in
H295R cells.
H295R cells were treated with vehicle, 100 nM Ang II, 20 µM BAY 11-7082, BAY 11-7082/Ang II or
EtOH for 4 hours. RNA was isolated and reverse transcribed to synthesize cDNA. AT1R cDNA was
qunatitated by real time PCR using the Lightcycler system (Roche Diagnostics). The data were normalized
to GAPDH expression. Data are mean ± S.D. from three independent experiments.
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Figure 2.15 Inhibition of HDACs does not suppress Ang II-dependent downregulation of hAT1R in
H295R cells.
H295R cells were treated with vehicle, 100 nM Ang II, 400 nM TSA, TSA/Ang II or EtOH for 4 hours.
RNA was isolated and reverse transcribed to synthesize cDNA. AT1R cDNA was qunatitated by real time
PCR using the Lightcycler system (Roche Diagnostics). The data were normalized to GAPDH expression.
Data are mean ± S.D. from three independent experiments.
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DISCUSSION
The hAT1R plays a major role in a variety of physiological functions including
blood pressure regulation and has been implicated in cardiac hypertrophy.
understanding the regulation of its gene expression is very important.

Hence,

Here, we

investigated the regulation of its gene expression, after binding of its agonist Ang II, at
the transcriptional and post-transcriptional level.
Our studies with H295R cells showed that Ang II is involved in the
downregulation of AT1R mRNA (Fig. 2.1) and are similar to those observed in previous
studies in H295R cells (16, 17) and rat VSMCs (10).

PMA also leads to the

downregulation of AT1R mRNA (Fig. 2.2), suggesting that this downregulation may be
mediated by PKC. Previous studies have shown that PKC mediates the downregulation
of AT1R mRNA in H295R cells (16, 17), rat cardiomyocytes (25) and rat cardiac
fibroblasts (26). This suggests that the AT1R mRNA downregulation is mediated by
similar pathways in various tissues and species.

Preincubation of cells with

cycloheximide inhibits the downregulation of AT1R mRNA after subsequent Ang II
treatment. This suggests that protein translation is essential for the decrease in AT1R
steady state mRNA levels. Previous studies have shown that Ang II stimulates protein
synthesis by activation of Ca2+-sensitive-PKC pathway in human cardiac fibroblasts (27).
These data suggest that Ang II-dependent downregulation of hAT1R mRNA in H295R
cells may be mediated through the synthesis of a protein factor.
Transcriptional and post-transcriptional mechanisms are two possible pathways
by which the downregulation of mRNA can be mediated. Studies in rats have shown that
the downregulation of AT1R mRNA is regulated by post-transcriptional mechanisms (12,
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13). These studies in rats also identified the core sequence AUUUUA (12) on the 3′UTR of AT1R mRNA as the cis-element which mediates its degradation. Further studies
also showed that Ang II treatment leads to the phosphorylation of calreticulin and its
binding to this cis-element results in targeting of AT1R mRNA for degradation (13). But,
the mechanism for this degradation is not understood. Analysis of the hAT1R 3′-UTR
sequence showed the presence of two AUUUUA sequences at 273 and 877 bp
downstream from the stop codon. The context of the distal sequence has a very high
homology to the rat sequence (Fig. 2.4). 3′-RACE studies showed that the majority of
hAT1R mRNAs harbor this sequence suggesting that this putative destabilization
sequence may be involved in the downregulation of hAT1R mRNA by targeting the
mRNA for degradation. The analysis of hAT1R 3′-UTR also identified three AUUUA
pentamers, class I ARE (22), present 343, 699 and 857 bp downstream from the stop
codon. These elements have been known to be involved in the stability of early response
gene mRNA’s such as c-fos, c-myc, c-jun, junB and nur77 (28).
In vitro cell-free RNA degradation assay showed that the rate of degradation of
the full-length hAT1R 3′-UTR does not change when incubated with the cytoplasmic
extract isolated from H295R cells treated with Ang II for 0, 1, 2 and 4 hours, as the
downregulation reaches the maximum within 4 hours (Fig. 2.5). These data suggest that
downregulation of hAT1R mRNA may not involve AUUUUA element mediated
destabilization of hAT1R mRNA. In contrast, studies in rats have shown that the rate of
degradation of in vitro transcribed AT1 mRNA incubated with polyribosomal preparation
from Ang II-treated VSMCs have a higher rate of degradation than extracts from
untreated cells (12).

The half-lives of the mRNA incubated with the different
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cytoplasmic extracts were approximately 12 minutes. The half-life of the mRNA in the
in vitro assay is much shorter than that observed in the Northern assay (~2.5 h, Fig. 2.1).
This difference may be due to absence of 5′-cap and polyadenylation in the in vitro
transcribed mRNA, as polyA sequences are bound by PABPs and prevent the mRNA
from deadenylation, decapping and degradation.
To validate the results of the in vitro RNA degradation assay, fusion constructs of
firefly luciferase with various hAT1R 3′-UTR fragments were generated. The fusion
constructs were transfected into H295R cells; pGL3 promoter and pGLPRO plasmids
were transfected to serve as controls and phRG-B was used as control for transfection.
The luciferase activity in the Ang II-treated cells transfected with various luciferasefusion constructs did not show any decrease in the luciferase activity. This suggests that
the 3′-UTR addition to the luciferase does not cause any increase in destabilization of the
luciferase mRNA. However, there may be a small but significant increase in the stability
of the luciferase mRNA when fused to the full-length or distal 3′-UTR.
The luciferase assay shows the protein activity and indirectly the amount of
mRNA present in the cells. To determine whether the data from the luciferase assay was
a fair representation of the change in stability of the mRNA, β-globin reporter system
was utilized (29). In addition, luciferase mRNA has a very short half-life as Northern
assay showed only its degradation products (data not shown). β-globin mRNA on the
other hand has a long half-life (30) and has been extensively used in the study of 3′-UTRmediated destabilization of various mRNAs (29, 30-32). Fusion constructs of β-globin
with various 3′-UTR regions were generated and transfected into H295R cells. The
effect of Ang II treatment on their level was monitored by Northern assay. The results
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from the β-globin Northern assay suggest that mRNA from Ang II-treated cells are
stabilized rather than degraded (Fig. 2.8). Previous studies have shown that stimulation
with mitogens leads to the stabilization of some cytokine mRNAs such as granulocyte
macrophage-colony stimulating factor mRNA (32-35). These experiments suggest that
the AUUUUA sequence in the 3′-UTR by itself is not involved in the Ang II-mediated
degradation of hAT1R mRNA in H295R cells. This is in contrast to the regulation of
rAT1AR which has been shown to be degraded in an Ang II-dependent manner (12, 13).
The 5′-UTR and 3′-UTR of mRNA are brought together by RNA binding proteins
to form a circular RNA (36). Efficient translation of mRNAs require the presence of both
5′-cap and polyadenylation at the 3′-end. Absence of either of them leads to a decrease in
the translational efficiency of the mRNA. Cap binding protein eIF4E and PABP interact
through a complex of proteins, eIF4G, eIF3, eIF4Aand PAIP, to form the circular mRNA
(24). It is speculated that a similar mechanism may be involved in the regulation of
mRNAs. Then the presence of both the 5′-UTR and 3′-UTR would be essential for the
regulation of the mRNA. In addition, the 5′-UTR of hAT1R mRNA has been implicated
in its degradation in rats (15). The role of hAT1R 5′-UTR in the degradation was
investigated by utilizing luciferase fusion constructs that harbor both 5′-UTR and 3′-UTR
or 5′-UTR alone. These experiments showed that Ang II treatment did not lead to
degradation of mRNA harboring the 5′- and 3′-UTRs of hAT1R mRNA (Fig 2.9). In
addition, the luciferase activity after Ang II treatment increased by 50% similar to the
luciferase- and the β-globin-3′-UTR fusion experiment described above. The results
from all the experiments above showed that the Ang II-stimulated downregulation of
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hAT1R mRNA is not mediated by the 5′- and 3′-UTRs. This suggests that the coding
region may harbor cis-elements that are responsible for the Ang II-mediated degradation
of hAT1R mRNA. Previous studies have identified the presence of cis-elements that
mediate mRNA destabilization in the coding regions of certain mRNAs such as c-myc
(37) and c-fos (38). However, it is possible that downregulation of hAT1R mRNA may
not be caused by destabilization of mRNA, but is caused by transcriptional inhibition of
the gene.
To determine whether Ang II stimulation of H295R cells led to degradation of
hAT1R mRNA, experiments were performed in the presence of transcriptional inhibitor,
actinomycin D. Cells were pretreated with actinomycin D to inhibit the transcriptional
machinery from synthesizing new mRNAs. Then, the cells were treated with Ang II in
addition to actinomycin D; while control cells were treated with actinomycin D only.
The degradation of hAT1R mRNA was followed over time for six hours. The RNA
isolated from the cells were reverse transcribed with oligodT and quantitated using realtime PCR. The hAT1R mRNA was quantitated relative to GAPDH mRNA and the
GAPDH mRNA was quantitated using an external standard curve of known GAPDH
mRNA. The actinomycin D inhibition assay showed that simultaneous activation of the
cells with Ang II in addition to inhibition with actinomycin D did not lead to increased
rate of degradation of hAT1R mRNA compared to cells treated with actinomycin D alone
(Fig. 2.10). These data suggest that the Ang II-stimulated downregulation of hAT1R
mRNA is not mediated by destabilization of the mRNA and the there may not be any ciselements in the coding region that are involved in its degradation. To our knowledge,
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this is the first study to show that the Ang II-activated downregulation of hAT1R mRNA
in H295R cells is not post-transcriptionally regulated.
The results from all the experiments discussed above show that the
downregulation of hAT1R mRNA may be mediated transcriptionally. To investigate the
role of transcription in the downregulation of hAT1R mRNA, nuclear run-on assays were
performed as described in the Materials and Methods. The nuclear run-on assay showed
that Ang II stimulation of H295R cells leads to transcriptional inhibition of hAT1R
mRNA (Fig. 2.11). In comparison to untreated cells, the rate of transcription of hAT1R
mRNA decreased by 56% and 30% after 1 and 2 hours of Ang II treatment, respectively.
The Northern assay showed that the downregulation of hAT1R mRNA at 1 and 2 hours
was 5% and 30%, respectively. This shows that although the transcriptional inhibition is
rapid, the downregulation of the mRNA already present in the cells is slow, resulting in
higher estimate using the Northern assay. Previous studies in rats have shown similar
results that Ang II-mediated AT1R mRNA downregulation is transcriptionally controlled
(6, 10, 39). Ang II showed a decrease in rAT1R mRNA transcription by 50% (10) while
growth factors EGF, bFGF and PDGF-BB led to a reduction of transcription by 28%,
29% and 17%, respectively (9).
To validate the nuclear run-on assay, promoter activity assays were performed
utilizing a chimeric construct in which the promoter sequence of hAT1R gene, -1003 to
+39 bp and -2882 to +5, were subcloned upstream of the Renilla luciferase gene. H295R
cells transfected with the chimeric construct phRG-B-1003 were treated with Ang II for
various period and the luciferase activity was measured. The results from this experiment
showed that there is a small decrease in the normalized luciferase activity. However, the
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luciferase activity of cells transfected with the control plasmid, without the promoter, also
showed a similar decrease in the luciferase activity. Careful examination of the data
showed that the actual Renilla luciferase activity did not change in response to the Ang II
stimulation. The decrease in the relative luciferase activity is due to the increase in the
activity of pGL3 control plasmid cotransfected for the normalization of the transfection
efficiency. To eliminate this artifact, cells were then transfected with phRG-B-2882 and
the luciferase activity was measured after treatment with 100 nM Ang II for various
period. The luciferase data was normalized against the total protein measurement. Fig.
2.13 shows no significant change in the luciferase activity in response to Ang II
treatment. Studies conducted in VSMCs by Ichiki et al. shows a similar result where
there is no significant change in the luciferase activity (40). However, it has to be noted
that the Ang II treatment in their experiment was 24 hours. There are two possibilities
for not being able to observe the Ang II-mediated decrease in luciferase activity in the
promoter assay as expected from the results of nuclear run-on assay; 1) The cis-element
that is involved in the Ang II-mediated transcriptional inhibition is not present in the
region that we were investigating using the promoter assay. In theory, the regulatory
element that controls the Ang II-dependent transcriptional change may be present
anywhere upstream of the transcriptional start site of hAT1R; 2) The 39 bases from exon
1 included in our construct may interfere with the experiments as this region has been
reported to be associated with cap-independent translational initiation (41).

This

increased translatability of the luciferase mRNA in addition to the stabilization of the
mRNA due to Ang II treatment observed in our luciferase experiments might be
responsible for lack of transcriptional inhibition observed in the promoter assays
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Repression of genes by transcription factors is one of the ways a specific gene can
be turned off. Recent studies suggests that transcription factor NF-κB can act as a
transcriptional repressor (42-44). Transcription factor binding site analysis of the hAT1R
gene sequence identified the presence of five semiconsenus NF-κB sites. Two of the
sites, -532 and -1247, are present upstream of the transcription start site, while the
remaining were present downstream at +1237, +1504 and +3456. To determine whether
NF-κB may be involved in the Ang II-mediated downregulation of hAT1R mRNA, NFκB inhibition assays were performed. BAY 11-7082 treatment alone lead to a decrease
in the hAT1R mRNA level by 50 %. Addition of Ang II to the cells following the BAY
11-7082 lead to decreased the mRNA levels to 19 %, a 60 % decrease from BAY 117082 treatment alone. This is similar to the downregulation observed in response to Ang
II in cells that were not pretreated with BAY 11-7082. Treatment of H295R cells with
EtOH, solvent for BAY 11-7082, did not significantly affect the hAT1R mRNA level.
The results from these experiments showed that inhibition of NF-κB does not lead to
decrease in Ang II-dependent downregulation of hAT1R mRNA suggesting that NF-κB
may not be involved in the Ang II-mediated downregulation of hAT1R mRNA.
HDACs are also involved in the repression of gene expression. HDACs alter the
structure of chromatin in the nucleus by catalyzing the deacetylation of histones leading
to increased binding of DNA strands to the histone complexes (45). To examine whether
HDACs play a role in the Ang II-mediated downregulation of hAT1R mRNA, H295R
cells were pretreated with TSA followed by incubation with Ang II. Pretreatment of cells
with TSA did not rescue the Ang II mediated downregulation of hAT1R mRNA. TSA
treatment alone downregulated hAT1R mRNA to 78 % while additional incubation with
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Ang II for four hours downregulated the mRNA level to 40 %. However, hAT1R mRNA
was not significantly downregulated in cells treated with ethanol alone. These data
suggests that the Ang II-dependent downregulation of hAT1R mRNA may not be
mediated by HDACs.
Ang II stimulation of AT1R leads to the production of reactive oxygen species
(ROS) in VSMCs (46), vascular endothelial cells (47) and vascular fibroblasts (48). ROS
has been recently shown to be involved in the downregulation of hAT1R mRNA.
Research in rat VSMCs has shown that preincubation of cells with N-acetylcysteine
(NAC), a potent antioxidant, inhibits the Ang II-induced downregulation (40). However,
diphenylene iodonium (DPI), a specific inhibitor of NADH/NADPH oxidase, did not
inhibit the Ang II-mediated downregulation of hAT1R mRNA. This suggests that other
pathways may lead to production of ROS like O2- that may be involved in this
downregulation. Ang II through ROS stimulates activator protein-1 (AP-1) activity and
c-jun/c-fos heterodimer binding activity (49). This study also showed that the Ang IIinduced protein synthesis is blocked by pretreatment of differentiated myotubes with
NAC. This taken together with our data, where cycloheximide pretreatment inhibited the
Ang II-mediated downregulation of hAT1R mRNA, suggests that ROS may be involved
in this downregulation in H295R cells.
In conclusion, Ang II treatment leads to a significant downregulation of the AT1R
in H295R cells. We have demonstrated that the 3′-UTR and the 5′-UTR of the mature
mRNA are not involved in the degradation. Additionally, we have utilized nuclear runon assay and demonstrated that the downregulation of the AT1R mRNA is
transcriptionally controlled.
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However, further experiments need to be performed to

validate this independently. In addition, the mechanisms by which Ang II mediates the
transcriptional inhibition of hAT1R gene expression need to be elucidated.
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